Another Setback For Santhera’s Idebenone DMD Hopes
EU Opinion On Marketing Suitability Is Delayed To Year-End
Santhera needs more time to address concerns regarding its current EU application for idebenone in the DMD setting but the Swiss biotech is keeping its sights on a broader indication.
